Innovent Biologics (IVBIY) เผยผลการทดลองโรคมะเร็งที่มีแนวโน้มดี พร้อมอัตราการตอบสนองของเนื้องอกที่สูง

Innovent Biologics announced highly promising clinical trial outcomes for two key oncology therapies, specifically highlighting the combination of IBI354 with pertuzumab in cancer treatment regimens. The trial data demonstrated impressive tumor response rates and manageable safety profiles, bolstering confidence in the therapeutic efficacy of these drug candidates. Medical researchers and investors viewed the results as a significant milestone for the company's expanding oncology portfolio. Successful clinical progression paves the way for potential regulatory submissions and expanded commercial opportunities in major global markets. This breakthrough underlines the growing effectiveness of targeted combination therapies in addressing difficult-to-treat malignancies. Market sentiment surrounding the company's biotechnology pipeline has strengthened following the public disclosure of these robust trial outcomes.